Company news

Rein Therapeutics, Inc. news in 2025

Rein Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

November 6, 2025

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

November 3, 2025

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

October 9, 2025

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

September 17, 2025

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

August 19, 2025

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

August 14, 2025

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

July 30, 2025

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

April 15, 2025

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

April 7, 2025

Aileron Therapeutics Announces Rebranding to Rein Therapeutics

January 9, 2025